Drug Profile

CDR 813

Alternative Names: CDR-813

Latest Information Update: 20 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator CDR-Life
Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

15 Sep 2024 Pharmacodynamics data from a preclinical trial in Solid tumours released by CDR-Life
13 Sep 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
06 Aug 2024 Preclinical trials in Solid tumours in Switzerland (Parenteral) (CDR life pipeline, August 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com